IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

B Cells Transduced with HPV16 E6/E7-expressing Adenoviral Vector Can Efficiently Induce CTL-dependent Anti-Tumor Immunity

  • Kim, Yun-Sun (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Ko, Hyun-Jeong (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Kim, Yeon-Jeong (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Han, Seung-Hee (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Lee, Jung-Mi (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Chang, Woo-Sung (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Jin, Hyun-Tak (Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology) ;
  • Sung, Young-Chul (Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology) ;
  • Kang, Chang-Yuil (Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
  • Published : 2007.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Human papillomavirus (HPV) infection is responsible for cervical cancer, a common cancer in women. Since HPV infection and cancer development are controlled by the host immune system, immunotherapy against HPV can be helpful in preventing or treating HPV-associated cervical cancer. Two oncoproteins of HPV16, E6 and E7, are promising targets for immunotherapy against cervical cancer, because they are constitutively expressed in cervical cancer. Methods: Since cellular vaccines using B cells as well as dendritic cells offer an efficient approach to cancer immunotherapy, we opted to use B cells. We evaluated the immunogenicity and anti-tumor effects of a B cell vaccine transduced with HPV16 E6/E7-expressing adenovirus. Results: Vaccination with HPV16 E6/E7-transduced B cells induced E6/E7-specific $CD8^+$ T cell-dependent immune responses and generated anti-tumor effects against E6/E7-expressing TC-1 tumor. The anti-tumor effect induced by this B cell vaccine was similar to that elicited by DC vaccine, showing that B cells can be used as an alternative to dendritic cells for cellular vaccines. Conclusion: Thisstudy has shown the feasibility of using B cells as immunogenic APCs and the potential for developing prophylactic and therapeutic vaccines against HPV-associated cervical cancer using a B cell vaccine transduced with adenovirus expressing HPV16 E6/E7.

Keywords

References

  1. Woodman CB, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7;11-22, 2007 https://doi.org/10.1038/nrc2050
  2. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2;342-350, 2002 https://doi.org/10.1038/nrc798
  3. Tindle RW: Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2;59-65, 2002 https://doi.org/10.1038/nrc700
  4. Roden R, Wu TC: How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6;753-763, 2006 https://doi.org/10.1038/nrc1973
  5. Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Muller-Holzner E, Pawlita M, Pfister H, Fritsch P: Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356;1985-1986, 2000 https://doi.org/10.1016/S0140-6736(00)03315-8
  6. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D: Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11;4717-4723, 2005 https://doi.org/10.1158/1078-0432.CCR-04-2599
  7. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, Guimaraes V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, Gruss A, Langella P: A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175;7297-7302, 2005 https://doi.org/10.4049/jimmunol.175.11.7297
  8. Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC: Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-rumor immunity. Gene Ther 7;726-733, 2000
  9. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, Hardwick JM, Wu TC: Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 171;2970-2976, 2003 https://doi.org/10.4049/jimmunol.171.6.2970
  10. Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF, Lai CH: A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 13;481-488, 2006 https://doi.org/10.1007/s11373-006-9086-6
  11. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW: Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70;960-965, 1996
  12. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5;296-306, 2005 https://doi.org/10.1038/nri1592
  13. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392;245-252, 1998 https://doi.org/10.1038/32588
  14. Schultze JL, Grabbe S, von Bergwelt-Baildon MS: DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol;25:659-664, 2004 https://doi.org/10.1016/j.it.2004.09.016
  15. Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF: Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol 139;458-467, 2005 https://doi.org/10.1111/j.1365-2249.2005.02733.x
  16. Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR: B cells directly tolerize CD8(+) T cells. J Exp Med 188;1977-1983, 1998 https://doi.org/10.1084/jem.188.11.1977
  17. Eynon EE, Parker DC: Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175;131-138, 1992 https://doi.org/10.1084/jem.175.1.131
  18. Raimondi G, Zanoni I, Citterio S, Ricciardi-Castagnoli P, Granucci F: Induction of peripheral T cell tolerance by antigen-presenting B cells. I. Relevance of antigen presentation persistence. J Immunol 176;4012-4020, 2006 https://doi.org/10.4049/jimmunol.176.7.4012
  19. Rodriguez-Pinto D: B cells as antigen presenting cells. Cell Immunol 238;67-75, 2005 https://doi.org/10.1016/j.cellimm.2006.02.005
  20. Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, Tanimoto M, Harada M, Takahashi T, Akatsuka Y: Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 169;2164-2171, 2002 https://doi.org/10.4049/jimmunol.169.4.2164
  21. Zentz C, Wiesner M, Man S, Frankenberger B, Wollenberg B, Hillemanns P, Zeidler R, Hammerschmidt W, Moosmann A: Activated B cells mediate efficient expansion of rare antigen-specific T cells. Hum Immunol 68;75-85, 2007 https://doi.org/10.1016/j.humimm.2006.12.004
  22. Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH, Kang CY: CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 66;6843-6850, 2006 https://doi.org/10.1158/0008-5472.CAN-06-0889
  23. Gallo P, Dharmapuri S, Cipriani B, Monaci P: Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther; 12 Suppl 1;S84-91, 2005 https://doi.org/10.1038/sj.gt.3302619
  24. Xia D, Moyana T, Xiang J: Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 16;241-259, 2006 https://doi.org/10.1038/sj.cr.7310032
  25. Lyakh LA, Koski GK, Young HA, Spence SE, Cohen PA, Rice NR: Adenovirus type 5 vectors induce dendritic cell differentiation in human CD 14(+) monocytes cultured under serum-free conditions. Blood 99;600-608, 2002 https://doi.org/10.1182/blood.V99.2.600
  26. Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfield LH, Dorsky DI, Economou JS, Mukherji B, Chakraborty NG: Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology 113;472-481, 2004 https://doi.org/10.1111/j.1365-2567.2004.01978.x
  27. Jin HT, Youn JI, Kim HJ, Lee JB, Ha SJ, Koh JS, Sung YC: Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther 16;328-338, 2005 https://doi.org/10.1089/hum.2005.16.328
  28. Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76;287-299, 1994 https://doi.org/10.1016/0092-8674(94)90336-0
  29. Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, Glaubitz M, Niesert S, Kuhnle H, Schedel I: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 57;836-840, 1994 https://doi.org/10.1002/ijc.2910570612
  30. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3; 133-146, 2003 https://doi.org/10.1038/nri1001